A new stem cell therapy shows promise in treating hair loss, but skepticism remains about its availability. Users humorously discuss the effectiveness of treatments on mice compared to humans.
The conversation discusses maintaining hair regrowth using minoxidil and finasteride and whether using gt20029, which degrades androgen receptors, would affect this. Fluridil, a similar treatment, can disable over 90% of active androgen receptors.
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
The conversation discusses using topical finasteride (0.25% gel) and minoxidil (5% foam) for hair loss, with users sharing experiences about application methods, microneedling, and results. Some users have switched to oral finasteride for convenience and cost-effectiveness, while others discuss the greasy nature of the topical solution.
Topical finasteride results in plasma levels 100 times lower than oral finasteride, potentially reducing systemic side effects. Users report similar efficacy with fewer side effects, suggesting a preference for topical application.
Minoxidil foam absorption concerns, with suggestions to use gloves or apply directly to the scalp to ensure proper absorption. Some users recommend using a scalp massager or switching to liquid minoxidil for better application.
The conversation discusses the effectiveness of topical Rapamycin for hair regrowth and color restoration. Specific treatments mentioned are Minoxidil, Finasteride, and RU58841.
The relative strength of Pyrilutamide compared to RU58841 in terms of androgen receptor binding affinity. It has been noted that Pyrilutamide is 4x stronger than RU58841, with a higher binding affinity than DHT itself.
Discussion on hair loss treatments, focusing on pp405, with skepticism about its effectiveness and concerns about its association with the cosmetic industry. Users also mention treatments like Minoxidil and Finasteride.
The conversation discusses using 23andme to determine if someone might respond well to minoxidil for hair loss treatment, and mentions the user's personal experience with micro-needling and minoxidil.
Placebo hair regrowth might be influenced by propylene glycol in lotions or participants lying about using other treatments like minoxidil, finasteride, or microneedling. Being part of a study can also improve hair health due to lifestyle changes.
User discusses using trichosol as a vehicle for hair loss treatments like finasteride and minoxidil. They ask about others' experiences and the stability of the solutions.
People are discussing the group buy and availability of KX-826 for hair loss treatment, with shipments expected around March-April. There is interest in finding more information and joining future group buys.
The conversation discusses using homemade topical finasteride for hair loss, showing an increase in DHT levels despite treatment. The user applies 0.125mg daily, resulting in 113.4% of previous DHT levels.
A user is using a topical treatment called Formula 82f, which contains finasteride, minoxidil, and a steroid, along with Ketoconazole shampoo for hair loss. They are considering whether to switch to oral medication for better results.
The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.
A potential alternative to Minoxidil for hair loss is discussed, specifically a sugar hydrogel. Users express skepticism about new treatments becoming reality.
Kintor's phase III trial for pyri (KX-826) showed promising safety and efficacy results, with no drug-related sexual dysfunction reported. Users discussed their experiences with pyri, Minoxidil, Dutasteride, and concerns about the validity of the study results.
Verteporfin and FAK inhibitors being looked at as potential treatments for hair regeneration, with updates on the unofficial off-label human trial being discussed.
A user plans to create a DIY topical treatment for hair loss using Rapamycin, possibly combined with alpha-ketoglutaric acid (a-KG). They discuss the concentration and formulation process for Rapamycin, considering safety and skin penetration, and intend to apply it every other day to the scalp.
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
Pelage, backed by Google Ventures, is seen as a promising company potentially finding a cure for hair loss using stem cell activation. There is skepticism and optimism among users, with some awaiting results from ongoing trials.
The conversation is about comparing the effectiveness of 5% RU58841 and 0.5% pyrilutamide for hair loss treatment. The user is asking if the higher concentration of RU58841 makes it stronger than the lower dose of pyrilutamide.
Tazarotene may be more effective than tretinoin when combined with topical minoxidil for hair loss due to its selective binding to RAR-beta and gamma, though it can cause irritation. Tazarotene's potency can lead to indirect inflammatory reactions despite potentially causing less irritation than tretinoin.
The conversation discusses starting finasteride 1mg daily for hair loss and mentions a high baseline DHT level. Users comment on the unusually high DHT level and its potential causes.
Mixing RU58841 with a solution for hair loss treatment, with suggestions to use propylene glycol and ethanol instead of k&b solution due to scalp irritation. Recommendations include using ketoconazole shampoo for itchiness and considering oral minoxidil if topical causes irritation.
User is using a homemade topical treatment with .015% finasteride, 5% minoxidil, and microneedling at .75mm depth. They also use 2% ketoconazole shampoo, various oils, and are considering increasing finasteride concentration due to mixed results.
The conversation humorously discusses a visit to the Everychem laboratory, with a focus on hair loss treatments like Minoxidil, finasteride, and RU58841. The tone is satirical.
Topicals like minoxidil and finasteride should reach the scalp, but excessive massaging can cause hair to fall out. The evaporation felt is likely the carrier substances like alcohol or propylene glycol.